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Recent analysis indicated that afatinib could be effective in treating non-small cell lung cancer harboring
uncommon EGFR mutations. A 59-year-old man undergoing hemodialysis for chronic renal failure was
diagnosed with adenocarcinoma of the lung (cT4N3M1b). EGFR mutation analysis of his cancer revealed
G719A point mutation in exon 18, and we started daily administration of 30 mg afatinib with hemo-
dialysis (three times a week). As the feasibility of afatinib in patients with chronic renal failure under-
going hemodialysis has not been established, we analyzed the pharmacokinetics of afatinib in this pa-
tient. The trough level of afatinib in his plasma was almost similar to that of patients with normal renal
function. Two months later there was marked tumor shrinkage, indicating a partial response. Our results
suggest that afatinib could be safely administered and may exhibit good tumor response in a patient who
has advanced lung adenocarcinoma with uncommon mutations undergoing hemodialysis.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic kidney disease (CKD) is irreversible and can progress to
end-stage renal disease (ESRD), which is fatal without dialysis or
kidney transplantation. Compared with patients with normal
kidney function, patients with CKD are more likely to develop
cancers and to die from them [1–3]. Recently, improved manage-
ment of ESRD has led to increased survival for patients who suffer
from both cancer and ESRD.
Epidermal growth factor receptor (EGFR) is a transmembrane
receptor expressed on the surface of epithelial cells. Mutations of
EGFR gene are commonly observed in patients with non-small-cell
lung cancer (NSCLC) and are a predictor of efﬁcacy for treatment
with the EGFR tyrosine kinase inhibitor. The EGFR mutation po-
sitive rate in adenocarcinoma patients is approximately 10–15% in
Caucasian patients and 30–40% in Asian patients [4,5].
Afatinib is an orally active, irreversible covalent inhibitor of
ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H
strain) receptor family members, including EGFR, ErbB2/HER2, and
ErbB4/HER4. Afatinib is a standard ﬁrst-line therapy for advancedLtd. This is an open access article u
chi).NSCLC with common activating EGFR mutations. Recent analysis
indicated that afatinib also showed a sensitivity to other un-
common mutations of EGFR gene, such as G719X in exon 18 and
L861Q in exon 21, which account for less than 10% of EGFR mu-
tations [6]. However, the feasibility of afatinib in patients with
ESRD undergoing hemodialysis is not clear.
Here, we present the clinical course and pharmacokinetic (PK)
analysis data of a patient with lung adenocarcinoma with G719A
EGFR mutation administered with afatinib undergoing hemodialysis.2. Case report
The patient was a 59-year-old man, an ex-smoker with chronic
renal failure who had been undergoing hemodialysis for 17 years.
He was diagnosed with advanced adenocarcinoma of the lung in
stage cT4N3M1b with multiple pulmonary, bone and hepatic
metastases in February 2015. Mutation analyses of the tumor
biopsy revealed G719A point mutation in exon 18 of EGFR. He had
Eastern Cooperative Oncology Group performance status 0 and
adequate organ function except for ESRD. We started afatinib ad-
ministration once a day (30 mg/day, orally) and performed PK
analysis after obtaining his written informed consent. Blood
samples were taken immediately before dosing (24 h after the last
dosing) on days 2, 3, 10, 11, and 12. Plasma concentrations ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Pre-dose plasma concentrations of afatinib. Arrows indicate 30 mg afatinib
administration. HD shows hemodialysis.
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dem mass spectrometry (LC–MS/MS) methods using a multiple
reaction-monitoring mode. The LC–MS/MS system was composed
of Nexera X2 ultra-high-performance liquid chromatography
(Shimadzu Co., Kyoto, Japan) and LCMS-8040 triple quadrupole
mass spectrometer equipped with an ESI ion source (Shimadzu).
As shown in Fig. 1, pre-dose concentration in plasma im-
mediately before the administration of the next dose (Cpre) was
10.2 ng/ml on day 2 and 15.7 ng/ml on day 3. Cpre increased to
22.8 ng/ml on day 10, 27.3 ng/ml on day 11 and 23.8 ng/ml on day
12, respectively. Therefore, we considered that steady-state plasma
concentrations to have been achieved by day 12 at the latest. The
treatment was well tolerated; the major toxicity during the ﬁrst
4 weeks was only grade 1 skin rash and there was no diarrhea
without using anti-diarrheal agents (e.g., loperamid). After con-
tinuation of afatinib for 2 months, he suffered from an infection of
his dialysis shunt. Methicillin-sensitive Staphylococcus aureus
(MSSA) was isolated from his two independent blood culture sets.
He was treated for MSSA bacteremia with antibacterial drugs with
favorable outcome. The tumors apparently shrank and CT scan
after the 2 months of afatinib treatment showed partial response
(Fig. 2).Fig. 2. CT scans of primary tumor before and after afatinib treatment. T3. Discussion
This is the ﬁrst PK study of afatinib in a patient with NSCLC
undergoing hemodialysis. The main route of excretion of afatinib is
via the feces (85%), with only minor excretion in urine following a
single oral dose of [14C]-labeled afatinib solution [7]. After afatinib
administration, peak plasma concentration levels are achieved by
2–5 h and the mean terminal half-life is 37 h in patients with
normal renal function. Steady-state plasma levels can be achieved
within 8 days of once daily oral dosing [8]. Several articles have
reported on the pharmacokinetic analysis of ﬁrst generation EGFR-
tyrosine kinase inhibitors (TKIs) administered for patients with
ESRD undergoing hemodialysis or continuous ambulatory perito-
neal dialysis [9–11]. Recently, Bersanelli et al. reported that geﬁ-
tinib and afatinib were safely administered to a patient with
NSCLC undergoing hemodialysis [12]. In this report, they started
30 mg per day of afatinib with a favorable safety proﬁle. However,
after they increased the afatinib dose to 40 mg, the patient showed
some symptoms of adverse effect and was unable to continue [12].
Thus, we chose 30 mg as the starting dose of afatinib in our
patient.
The plasma concentration of afatinib in our case had reached a
steady level on day 12 (Fig. 1). It was slightly higher than those
observed in patients with normal renal function who received
30 mg afatinib daily, but lower than those receiving 40 mg of
afatinib in a phase I study (Table 1) [13]. Afatinib is poorly re-
moved by hemodialysis, because over 95% of afatinib combines
with plasma protein [14]. As with other oral EGFR-TKIs, pharma-
cokinetics parameters of afatinib have inter-individual variability.
We speculate that the plasma concentration of afatinib in our
patient might be within individual variation among patients with
normal renal function. Although there has been insufﬁcient data
accumulation, it seems that afatinib could be safely administered
to ESRD patients undergoing hemodialysis.
First generation EGFR-TKIs, including geﬁtinib and erlotinib,
have shown a signiﬁcant PFS beneﬁt compared with cytotoxic
chemotherapy in NSCLC patients who have common activating
mutations, such as an exon 19 deletion or the L858R point muta-
tion [15,16]. Although uncommon mutations—including G719X in
exon 18 and L861Q in exon 21, which account for less than 10% of
EGFR mutations—also show a response to ﬁrst generation of EGFR-
TKI, the efﬁcacy of ﬁrst generation EGFR-TKI for uncommon mu-
tations is limited [17]. In a subgroup analysis of NEJ 002 study that
compared geﬁtinib and carboplatin-paclitaxel as ﬁrst-line treat-
ments for advanced NSCLC harboring uncommon mutation, the
overall survival of patients treated with geﬁtinib tended to bewo months after the initiation of afatinib, tumor obviously shrunk.
Table 1
Plasma concentration of afatinib in the present case and data from a previous study
of patients with normal renal function.
Parameter Present case Previous study [Ref. 13]
Afatinib dose (mg/day) 30 20 30 40
Days 12 28
Cpre
a (ng/ml) 23.8 14.3 14.4 33.7
a Pre-dose concentration in plasma immediately before administration of the
next dose.
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Recently, the second-generation EGFR-TKI afatinib has shown ef-
ﬁcacy in patients with uncommon mutations in additional ana-
lyses from the LUX-Lung 2, 3, and 6 trials [6]. Afatinib showed high
activity in patients with the uncommon EGFR mutation G719X,
L861Q and S768I mutations; median PFS 10.7 months and median
OS was 19.4 months. Thus, afatinib might be the best choice for
treatment of patients with NSCLC harboring certain types of un-
common EGFR mutations.
In the present case, skin rash was relatively mild and there was
no diarrhea. Notably, bacteremia occurred in this patient, which is
a frequent complication in patients undergoing dialysis. The
overall rate of bacteremia varies from 7.6 to 14.4 per 100 patient-
years [18–20]. However, our patient had undergone hemodialysis
for 17 years without any bacterial complications. Although his skin
complication of afatinib was minimal, it could not be denied that
skin toxicities of afatinib could contribute to the establishment of
bacterial location from skin to blood.4. Conclusion
Our results indicate that afatinib could be safely administered
to a patient with chronic renal failure. Trough plasma concentra-
tions in the present case on hemodialysis were comparable to
those in patients with normal renal function. Afatinib might be an
optimum agent for patients with uncommon mutations, including
G719X, because of their favorable anti-tumor activities and feasi-
bility, even with patients undergoing hemodialysis.Conﬂict of interest
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